Metabolomics predicts stroke recurrence after transient ischemic attack

Neurology

Volumn 84, Issue 1, 2015, Pages 36-45

  Jové, Mariona ^a   Mauri Capdevila, Gerard ^a   Suárez, Idalmis ^a   Cambray, Serafi ^a   Sanahuja, Jordi ^a   Quílez, Alejandro ^a   Farré, Joan ^b   Benabdelhak, Ikram ^a   Pamplona, Reinald ^a   Portero Otín, Manuel ^a   Purroy, Francisco ^a  

^a UNIVERSITY OF LLEIDA   (Spain)

^b UNIVERSITY OF LLEIDA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BIOLOGICAL MARKER; CLOPIDOGREL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LYSOPHOSPHATIDYLCHOLINE;

AGE; AGED; ANTICOAGULATION; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE; CEREBROVASCULAR ACCIDENT; CLINICAL FEATURE; DIABETES MELLITUS; FEMALE; HUMAN; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; METABOLOMICS; MULTIVARIATE ANALYSIS; PATTERN RECOGNITION; PLASMA; PREDICTION; PRIORITY JOURNAL; RATING SCALE; RECURRENT DISEASE; TRANSIENT ISCHEMIC ATTACK; BLOOD; BRAIN ATHEROSCLEROSIS; CEREBROVASCULAR DISEASE; COHORT ANALYSIS; COMPLICATION; DIFFUSION WEIGHTED IMAGING; ISCHEMIC ATTACK, TRANSIENT; MIDDLE AGED; PATHOLOGY; PROSPECTIVE STUDY; RISK ASSESSMENT; STROKE; TIME FACTOR; VERY ELDERLY;

AGE FACTORS; AGED; AGED, 80 AND OVER; BIOMARKERS; BLOOD PRESSURE; CEREBRAL SMALL VESSEL DISEASES; COHORT STUDIES; DIFFUSION MAGNETIC RESONANCE IMAGING; FEMALE; HUMANS; INTRACRANIAL ARTERIOSCLEROSIS; ISCHEMIC ATTACK, TRANSIENT; LYSOPHOSPHATIDYLCHOLINES; MALE; METABOLOMICS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDIES; RECURRENCE; RISK ASSESSMENT; STROKE; TIME FACTORS;

EID: 84924735029     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000001093     Document Type: Article

References (38)

1. Heuschmann PU, Di Carlo A, Bejot Y, et al. Incidence of stroke in Europe at the beginning of the 21st century. Stroke 2009;40:1557-1563.
2. Rothwell PM, Warlow CP. Timing of TIAs preceding stroke: time window for prevention is very short. Neurology 2005;64:817-820.
3. Merwick A, Kelly PJ. Transient ischaemic attack clinics and management of transient ischaemic attacks. Curr Opin Neurol 2011;24:50-58.
4. Purroy F, Montaner J, Molina CA, Delgado P, Ribo M, Alvarez-Sabín J. Patterns and predictors of early risk of recurrence after transient ischemic attack with respect to etiologic subtypes. Stroke 2007;38:3225-3229.
5. Ois A, Gomis M, Rodríguez-Campello A, et al. Factors associated with a high risk of recurrence in patients with transient ischemic attack or minor stroke. Stroke 2008;39: 1717-1721.
6. Purroy F, Jiménez-Caballero PE, Gorospe A, et al. Prediction of early stroke recurrence in transient ischemic attack patients from the PROMAPA study: A comparison of prognostic risk scores. Cerebrovasc Dis 2012;33: 182-189.
7. Purroy F, Montaner J, Molina CA, et al. C-reactive protein predicts further ischemic events in transient ischemic attack patients. Acta Neurol Scand 2007;115:60-66.
8. Katan M, Nigro N, Fluri F, et al. Stress hormones predict cerebrovascular re-events after transient ischemic attacks. Neurology 2011;76:563-566.
9. Delgado P, Chacón P, Penalba A, et al. Lipoprotein-associated phospholipase A(2) activity is associated with large-artery atherosclerotic etiology and recurrent stroke in TIA patients. Cerebrovasc Dis 2012;33:150-158.
10. Whiteley W, Tian Y, Jickling GC. Blood biomarkers in stroke: research and clinical practice. Int J Stroke 2012;7: 435-439.
11. Cucchiara BL, Messe SR, Sansing L, et al. Lipoproteinassociated phospholipase A2 and C-reactive protein for risk-stratification of patients with TIA. Stroke 2009;40: 2332-2336.
12. Purroy F, Suárez-Luis I, Mauri-Capdevila G, et al. N-terminal pro-brain natriuretic peptide level determined at different times identifies transient ischaemic attack patients with atrial fibrillation. Eur J Neurol 2014;21:679-683.
13. Mauri-Capdevila G, Jove M, Suarez-Luis I, Portero- Otin M, Purroy F. Metabolomics in ischaemic stroke, new diagnostic and prognostic biomarkers [in Spanish]. Rev Neurol 2013;57:29-36.
14. Jung JY, Lee HS, Kang DG, et al. 1H-NMR-based metabolomics study of cerebral infarction. Stroke 2011;42: 1282-1288.
15. Jiang Z, Sun J, Liang Q, et al. A metabonomic approach applied to predict patients with cerebral infarction. Talanta 2011;84:298-304.
16. Purroy F, Begué R, Gil MI, et al. Patterns of diffusionweighted magnetic resonance imaging associated with etiology improve the accuracy of prognosis after transient ischaemic attack. Eur J Neurol 2011;18:121-128.
17. Johnston SC, Rothwell PM, Nguyen-Huynh MN, et al. Validation and refinement of scores to predict very early stroke risk after transient ischaemic attack. Lancet 2007; 369:283-292.
18. Tsai TH, Chen YL, Lin HS, et al. Link between lipoprotein-associated phospholipase A2 gene expression of peripheral-blood mononuclear cells and prognostic outcome after acute ischemic stroke. J Atheroscler Thromb 2012;19:523-531.
19. Mannheim D, Herrmann J, Versari D, et al. Enhanced expression of Lp-PLA2 and lysophosphatidylcholine in symptomatic carotid atherosclerotic plaques. Stroke 2008;39:1448-1455.
20. Shanta SR, Choi CS, Lee JH, et al. Global changes in phospholipids identified by MALDI MS in rats with focal cerebral ischemia. J Lipid Res 2012;53:1823-1831.
21. Koizumi S, Yamamoto S, Hayasaka T, et al. Imaging mass spectrometry revealed the production of lysophosphatidylcholine in the injured ischemic rat brain. Neuroscience 2010;168:219-225.
22. Zhang Z, Lee YC, Kim SJ, et al. Production of lysophosphatidylcholine by cPLA2 in the brain of mice lacking PPT1 is a signal for phagocyte infiltration. Hum Mol Genet 2007;16:837-847.
23. Jin R, Yang G, Li G. Inflammatory mechanisms in ischemic stroke: role of inflammatory cells. J Leukoc Biol 2010; 87:779-789.
24. Farooqui AA, Horrocks LA. Phospholipase A2-generated lipid mediators in the brain: the good, the bad, and the ugly. Neuroscientist 2006;12:245-260.
25. Goncalves I, Edsfeldt A, Ko NY, et al. Evidence supporting a key role of Lp-PLA2-generated lysophosphatidylcholine in human atherosclerotic plaque inflammation. Arterioscler Thromb Vasc Biol 2012;32:1505-1512.
26. Cunningham TJ, Yao L, Lucena A. Product inhibition of secreted phospholipase A2 may explain lysophosphatidylcholines' unexpected therapeutic properties. J Inflamm 2008;5:17.
27. Pinto F, Brenner T, Dan P, Krimsky M, Yedgar S. Extracellular phospholipase A2 inhibitors suppress central nervous system inflammation. Glia 2003;44:275-282.
28. Blondeau N, Lauritzen I, Widmann C, Lazdunski M, Heurteaux C. A potent protective role of lysophospholipids against global cerebral ischemia and glutamate excitotoxicity in neuronal cultures. J Cereb Blood Flow Metab 2002;22:821-834.
29. Heurteaux C, Guy N, Laigle C, et al. TREK-1, a K1 channel involved in neuroprotection and general anesthesia. EMBO J 2004;23:2684-2695.
30. Rao SP, Riederer M, Lechleitner M, et al. Acyl chaindependent effect of lysophosphatidylcholine on endotheliumdependent vasorelaxation. PLoS One 2013;8:e65155.
31. Bir SC, Shen X, Kavanagh TJ, Kevil CG, Pattillo CB. Control of angiogenesis dictated by picomolar superoxide levels. Free Radic Biol Med 2013;63:135-142.
32. Liu Y, Jia H, Chang X, Ding G, Zhang H, Zou ZM. The metabolic disturbances of isoproterenol induced myocardial infarction in rats based on a tissue targeted metabonomics. Mol Biosyst 2013;9:2823-2834.
33. Hung ND, Kim MR, Sok DE. Anti-inflammatory action of arachidonoyl lysophosphatidylcholine or 15-hydroperoxy derivative in zymosan A-induced peritonitis. Prostaglandins Other Lipid Mediat 2009;90:105-111.
34. Krug S, Kastenmüller G, Stückler F, et al. The dynamic range of the human metabolome revealed by challenges. FASEB J 2012;26:2607-2619.
35. Enea C, Seguin F, Petitpas-Mulliez J, et al. (1)H NMRbased metabolomics approach for exploring urinary metabolome modifications after acute and chronic physical exercise. Anal Bioanal Chem 2010;396:1167-1176.
36. Park Y, Kim SB, Wang B, et al. Individual variation in macronutrient regulation measured by proton magnetic resonance spectroscopy of human plasma. Am J Physiol Regul Integr Comp Physiol 2009;297:R202- R209.
37. Patti GJ, Yanes O, Siuzdak G. Innovation: metabolomics: the apogee of the omics trilogy. Nat Rev Mol Cell Biol 2012;13:263-269.
38. Arboix A, Cabeza N, García-Eroles L, et al. Relevance of transient ischemic attack to early neurological recovery after nonlacunar ischemic stroke. Cerebrovasc Dis 2004; 18:304-311.